Evommune gains funding to accelerate therapies for chronic inflammatory diseases
2023-04-27
临床2期免疫疗法基因疗法
Preview
来源: Pharmaceutical Technology
Evommune focuses on the development of therapies to treat chronic inflammatory diseases. Credit: MasterTux from Pixabay.
Evommune has received $50m in Series B financing to accelerate the development of therapies for the treatment of chronic inflammatory diseases.
Co-led by new investor Arix Bioscience and current investors EQT Life Sciences and SymBiosis, the financing round also included new and existing investors such as Amplitude Ventures.
Recommended Reports
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Gene Therapy to Activate gp91phox for Chronic Granulomatous Disease GlobalData
Preview
来源: Pharmaceutical Technology
ReportsInnovation in Pharmaceuticals: immunotherapy for neurodegenerative disease GlobalData
View all
Pivotal bioVenture Partners and Andera Partners also participated in the company’s Series A funding round.
Arix Bioscience managing director Mark Chin stated: “As a new investor in Evommune, we are excited to partner with the company’s experienced leadership team, which leverages a unique human tissue screening platform to curate its drug discovery and translational medicine decisions.”
The funding will allow Evommune to advance three prioritised pipeline programmes that are focused on inflammatory diseases.
One of these programmes includes EVO101, a novel small molecule inhibitor that specifically targets the interleukin 1 receptor-associated kinase 4 (IRAK4) gene.
EVO101 is currently under assessment in a Phase 2a proof-of-concept trial involving patients diagnosed with atopic dermatitis. The company plans to release data from the trial later in 2023.
The company is also assessing the preclinical molecule, EVO756, which is designed to selectively modulate MRGPRX2 and target mast cells to treat diseases such as chronic spontaneous urticaria and interstitial cystitis.
The firm’s pipeline also includes a discovery-stage programme focused on autoimmune diseases through PKCθ.
Evommune president and CEO Luis Peña stated: “Evommune has multiple value-creating milestones planned over the next two years. We appreciate the continued support of our existing investors, and welcome new investors who share the vision and excitement about our programmes to evolve the immunology landscape.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。